Cure8 research brief
SMC phenotypic switching can contribute to intestinal fibrosis and motility problems in IBD; understanding macrophage regulation of SMCs could point to new treatment targets for these complications.
Researchers studying IBD pathogenesis, clinicians interested in IBD-related motility disorders and fibrosis, and translational scientists exploring immune–muscle interactions or microbiome influences.
This is a literature review (abstract level) summarizing mechanisms by which smooth muscle cells (SMCs) switch from a contractile to a synthetic phenotype in chronic inflammation.
The authors highlight macrophages as key regulators of SMC phenotypic switching and discuss pathways including inflammatory signaling, microbial interactions, and neural regulation.
The review frames the macrophage–smooth muscle axis as a conceptual pathway that could help explain IBD-associated motility disorders and intestinal fibrosis, and suggests this axis may offer targets for future therapy development. Because this is a review, it synthesizes existing studies rather than presenting new clinical trial results.
This entry is a published literature review (abstract-level summary provided). It synthesizes existing basic and translational studies rather than reporting new clinical trial findings. Clinical implications are speculative and would require targeted experimental or clinical studies to validate.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Declarations. Conflict of interest: The authors declare that they have no conflict of interest. Clinical trial registration: This article does not report any clinical trial data.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
If environmental microplastics contribute to gut dysbiosis and mucosal inflammation, this could help explain environmental triggers of ulcerative colitis and point toward prevention or microbiome-targeted interventions.
Research linking ETBF to intestinal inflammation and colorectal cancer suggests better detection and targeted therapies for this microbe could eventually affect IBD management and cancer risk assessment.
GPX and selenium-related pathways may be important to how oxidative stress, ferroptosis, and the microbiome contribute to IBD. Understanding these mechanisms could guide future therapies.
